BSE · 524752
Decipher Labs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-0 Cr — a -242.86% net margin, versus -7.69% the period before.
Shareholding
As of 2026-06-30
- Promoter16.43%
- Public83.57%
- FII0%
29,368 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.33× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #90 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,73,629 Cr | 38.11 | 5.67 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,20,143 Cr | 216.48 | 3.49 | 11.27% | 14% |
| Lupin Limited | ₹1,12,127 Cr | 70.41 | 4.99 | 23.76% | 19.4% |
| Zydus Lifesciences Ltd. | ₹1,12,000 Cr | 20.62 | 4.13 | 18.59% | 18.86% |
| Mankind Pharma Limited | ₹1,08,077 Cr | 194.71 | 6.63 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,478 Cr | 345.42 | 18.19 | 16.77% | 13.05% |
| Dr Reddys Laboratories Ltd. | ₹95,369 Cr | 431.17 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,231 Cr | 100.13 | 2.43 | 9.25% | 10.5% |
| Biocon Ltd. | ₹70,007 Cr | 546.71 | 2.06 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹68,056 Cr | 287.91 | 4.92 | 16.66% | 15.65% |
| Decipher Labs Limited(this company) | ₹6 Cr | — | 0.31 | -14.93% | -30.7% |
AI analysis
AI-generated · google/gemini-2.5-flashDecipher Labs Limited (524752) has a market capitalization of Rs 6 Cr. The company's 52-week high is Rs 11.66 and its 52-week low is Rs 5. The debt-to-equity ratio stands at 0.01.
Positives
- +The company's debt-to-equity ratio is very low at 0.01.
- +Promoter pledge is 0%, indicating no shares have been pledged by promoters.
Negatives
- −The company reported a negative profit margin of -30.7%.
- −Return on equity (ROE) is negative at -14.93%.
- −Return on capital employed (ROCE) is negative at -17.4076%.
- −The company has an EPS of 0.
- −The company is under GSM surveillance.
Financial Performance
Decipher Labs Limited reported quarterly revenue of Rs 3.6 Cr in Mar 2026, with a net profit of Rs -0.36 Cr. In the previous quarter, Dec 2025, revenue was Rs 3.21 Cr, with a net profit of Rs -0.54 Cr. The company's annual revenue was Rs 0.07 Cr in Mar 2026, generating a net profit of Rs -0.17 Cr for that period.
Profitability & Returns
The company reported a profit margin of -30.7%. Return on equity (ROE) was -14.93%, and return on capital employed (ROCE) was -17.4076%. Earnings per share (EPS) for the company is 0.
Balance Sheet
Decipher Labs Limited has a book value of Rs 20.47. The debt-to-equity ratio is 0.01, indicating a low level of debt relative to equity. The company does not currently offer a dividend, with a dividend yield of 0.
Ownership & Pledges
The total institutional holding is 0.003%. There are no pledged shares by the promoters.
Regulatory & Surveillance
The company is under GSM surveillance, specifically 'GSM 0', indicating close monitoring by regulatory bodies due to certain criteria being met. This measure suggests that the stock is subject to enhanced scrutiny to safeguard market integrity.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.